3-[(4-Azidophenyl)disulfanyl]propanoic acid | 79432-98-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-[(4-Azidophenyl)disulfanyl]propanoic acid
• CAS: 79432-98-7
• 化学式: C9H9N3O2S2
• 分子量: 255.3
• InChiKey: JNNKXAAIWMJRQM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  102
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  N-((4-叠氮基苯基)硫代)邻苯二甲酰亚胺 、 3-巯基丙酸 以70%的产率得到
  参考文献：
  名称：

  RAMASWAMI, V.;TIRRELL, D. A., AMER. CHEM. SOC. POLYM. PREPR., 1986, 27, N 1, 17-18

  摘要：

  DOI：

文献信息

• Chloroquine coupled nucleic acids and methods for their synthesis
  申请人：Kosak M. Kenneth

  公开号：US20060040879A1

  公开（公告）日：2006-02-23

  This invention discloses compositions and methods for preparing chloroquine-coupled nucleic acid compositions. The prior art has shown that chloroquines given as free drug in high enough concentration, enhances the release of various agents from cellular endosomes into the cytoplasm. The purpose of these compositions is to provide a controlled amount of chloroquine at the same site where the nucleic acid needs to be released, thereby reducing the overall dosage needed. The compositions comprise a chloroquine substance coupled to a nucleic acid directly or through a variety of pharmaceutical carrier substances. The carrier substances include polysaccharides, synthetic polymers, proteins, micelles and other substances for carrying and releasing the chloroquine compositions in the body for therapeutic effect. The compositions can also include a biocleavable linkage for carrying and releasing nucleic acids for therapeutic or other medical uses. The invention also discloses nucleic acid carrier compositions that are coupled to targeting molecules for targeting the delivery of nucleic acids to their site of action.

  本发明披露了制备氯喹偶联核酸组合物的组成和方法。先前的研究表明，以足够高的浓度给予氯喹作为自由药物，可以增强细胞内体内各种物质从内体泡中释放到细胞质中。这些组合物的目的是在核酸需要释放的同一位置提供受控量的氯喹，从而降低所需的总剂量。该组合物包括直接或通过各种药物载体物质偶联的氯喹物质和核酸。载体物质包括多糖、合成聚合物、蛋白质、胶束和其他用于在体内携带和释放氯喹组合物以达到治疗效果的物质。该组合物还可以包括生物可降解连接来携带和释放用于治疗或其他医疗用途的核酸。本发明还披露了偶联到靶向分子的核酸载体组合物，用于将核酸传递到其作用位置。
• Stable allergenic extracts and methods
  申请人：MINNESOTA MINING AND MANUFACTURING COMPANY

  公开号：EP0107832A2

  公开（公告）日：1984-05-09

  A storage-stable, high potency allergenic extract is prepared by ultrafiltration, retaining fractions having molecular weights of from 1000 to 100,000, and treating the solution with gel polymer and/or carbon absorbents. The extract is dried to a moisture content of less than one weight percent water. The purified solution and aqueous reconstituted solutions of the dried extract provide a transparent, colorless solution which has greatly increased stability, remaining transparent and colorless for extended periods.

  通过超滤，保留分子量在 1000 到 100,000 之间的馏分，并用凝胶聚合物和/或碳吸收剂处理溶液，制备出储存稳定的高活性过敏原提取物。提取物经干燥后，水分含量小于 1%。纯化后的溶液和干燥提取物的重配水溶液可提供透明无色的溶液，其稳定性大大提高，可长时间保持透明无色。
• Antibodies modified at two separate sites
  申请人：TECHNICLONE, INC.

  公开号：EP0783894A1

  公开（公告）日：1997-07-16

  Modified antibodies are disclosed which have been modified by chemical conjugation with a heterobifunctional reagent, such as SPDP. The use of these modified antibodies in the preparation of compositions for the diagnosis and therapy of cancer and other mammalian disease is also disclosed. These diagnostic uses include immunoscintography. The modified antibodies can be further conjugated with labels or biologically active molecules for use in such diagnosis and therapy.

  本研究公开了通过与杂多功能试剂（如 SPDP）进行化学共轭而修饰的抗体。还公开了这些修饰抗体在制备诊断和治疗癌症及其他哺乳动物疾病的组合物中的用途。这些诊断用途包括免疫镜检。经修饰的抗体可进一步与标签或生物活性分子连接，用于此类诊断和治疗。
• Agents that modulate EPH receptor activity
  申请人：The Burnham Institute

  公开号：EP1852441A2

  公开（公告）日：2007-11-07

  Novel agents are described that bind to Eph receptors. Methods of using these agents to modulate the activity of Eph receptors, stimulate apoptosis, and deliver therapeutic agents are also described. Methods of screening for agents capable of selectively binding to Eph receptors are also described.

  描述了与 Eph 受体结合的新型制剂。还描述了使用这些制剂调节 Eph 受体的活性、刺激细胞凋亡和递送治疗药物的方法。还介绍了筛选能够选择性地与 Eph 受体结合的制剂的方法。
• Particulate constructs for release of active agents
  申请人：CELATOR PHARMACEUTICALS, INC.

  公开号：US10905775B2

  公开（公告）日：2021-02-02

  Particulate constructs stabilized by amphiphilic copolymers and comprising at least one active coupled to a hydrophobic moiety provide sustained release of the active in both in vitro and in vivo environments.

  由两亲性共聚物稳定的微粒结构包含至少一种与疏水分子结合的活性物质，可在体外和体内环境中持续释放活性物质。